G
Genfit
Biotech & Life Sciences · Loos, France · Founded 1999 · IPO 2019
Develops drugs for the prevention and treatment of cardiometabolic and neurodegenerative diseases MoreLess
A late-stage biopharmaceutical company dedicated to the discovery and development of therapeutic solutions for severe and chronic liver diseases. The company focuses on areas with high unmet medical needs, leveraging its expertise in liver disease to advance its pipeline of drug candidates.
Genfit's business model is centered on the research and development of new drugs, from discovery to late-stage clinical trials. The company also engages in strategic partnerships and licensing agreements to commercialize its products and expand its research pipeline. A recent example is the licensing of the exclusive worldwide rights of the ASK1 Inhibitor SRT-015 from Seal Rock Therapeutics. The company's primary clients are patients suffering from rare and life-threatening liver diseases. Genfit operates in the global biopharmaceutical market, with a specific focus on hepatology.
Keywords: biopharmaceutical, liver disease, drug development, clinical trials, hepatology, rare diseases, drug discovery, ASK1 inhibitor, life sciences, therapeutics
Talent graph
Genfit's talent
Source: Dealroom Talent Intelligence.
Investors
2 investors on Genfit's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Genfit has talent and traffic
team presence
across markets
Patent intelligence
$139M patent portfolio · 77 active families
Where Genfit concentrates vs peers
Each axis is a top-10 topic across Genfit and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Market sentiment
What the market is saying about Genfit
An AI-synthesized read of the highest-engagement posts about Genfit on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genfit on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.